RxDoctor Payments Data

Dorothy Mathiesen

Adult Health · Aurora, CONPI 1598334849

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (57.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 64.4% of it on its own, with 5 other manufacturers making up the rest. Among adult health clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,800in general payments, 2019–2025

Across 42 payments — averaging $90.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abbott$883
  • Neurocrine Biosciences, Inc.$158
  • Acadia Pharmaceuticals Inc$114
  • Acorda Therapeutics, Inc$112
  • Merz Pharmaceuticals, LLC$85

What the payments were for

  • Travel & lodging$2,17357%
  • Food & beverage$1,45238%
  • Education$1755%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,800 in reported general payments places this provider in the 90th percentile of 430 adult health providers in Colorado.

See all adult health providers in Colorado

Medicare billing

Part B allowed, 2024
$86,983
Medicare patients
388
Services billed
1,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa162$316,049
IngrezzaValbenazine Tosylate11$162,517
NuplazidPimavanserin Tartrate28$143,044
AustedoDeutetrabenazine12$131,639
NourianzIstradefylline14$35,453
Carbidopa-LevodopaCarbidopa/Levodopa708$32,231
NeuproRotigotine15$26,208
Carbidopa-Levodopa ErCarbidopa/Levodopa235$18,026
Selegiline Hcl50$6,582
Rasagiline Mesylate33$5,987
Gabapentin148$4,768
Entacapone25$4,409
Primidone94$4,285
RivastigmineRivastigmine Tartrate48$2,835
Ropinirole ErRopinirole Hcl16$2,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$158$162,51711 claims
Acadia Pharmaceuticals IncNuplazid$114$143,04428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 430 adult health providers in Colorado.

Other adult health in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →